The Cleveland Clinic Foundation has entered into a settlement with the U.S. Department of Justice and the Ohio Attorney General, agreeing to halt all gender-related medical procedures and treatments for minors for 20 years [1]. The agreement covers puberty blockers, cross-sex hormones, and surgical interventions characterized by the government as sex-rejecting procedures [1]. The clinic also agreed to pay a $308,000 penalty and establish a $2 million fund designated for "restorative care" for individuals who allege harm from prior treatments [1].
The settlement resolves DOJ allegations that the Cleveland Clinic engaged in false billing practices related to gender-care services provided to minors, implicating the False Claims Act as a central enforcement vehicle [1]. The False Claims Act permits the federal government to pursue treble damages and civil penalties against entities that submit fraudulent claims for reimbursement to federal healthcare programs. The $308,000 payment addresses those billing allegations, while the restorative care fund operates as a separate remedial mechanism [1]. Stanley Woodward, a principal figure in the DOJ's enforcement posture on this issue, has been identified in connection with the broader campaign [1].
This agreement follows a structurally similar settlement the DOJ reached with Texas Children's Hospital, establishing a pattern of enforcement actions directed at major healthcare institutions that have offered gender-related care to pediatric patients [1]. The Trump administration has pursued this enforcement campaign as a national initiative, using civil litigation and settlement leverage rather than criminal charges to impose prospective operational restrictions on healthcare providers [1]. The Ohio Attorney General's participation signals coordinated state-federal enforcement, a model that amplifies both the reach and the durability of the restrictions imposed.
The 20-year prohibition is the most consequential structural element of the agreement, binding the Cleveland Clinic to treatment restrictions that will outlast any single administration or policy cycle. Whether the consent agreement will face legal challenge, including from affected patients, advocacy organizations, or the clinic itself under a future administration, remains an open question. Similar agreements with other major hospital systems are widely anticipated as the DOJ's enforcement campaign continues to expand to additional jurisdictions and providers.